STAT+: New federal rule will require prescription drug middlemen to share secret payments data

The rule requires pharmacy benefit managers, or PBMs, to give their employer clients a fuller picture of how PBMs are paid. Employers will learn about compensation from drugmakers, consulting firms, and other entities. This matters because employers use PBMs to oversee prescription drug spending for workers.

The disclosures will cover drug rebates and spread pricing. They will also include financial relationships with brokers and consultants. For example, an employer could learn that a PBM receives a rebate from a drugmaker or has a paid relationship with a consultant involved in benefits decisions.

The regulation was finalized by the Trump administration. Required disclosures begin July 1, 2027. Federal officials estimate the rule will cover more than 70 PBMs and 130,000 employers, potentially giving those employers protected information they can use when assessing their drug-benefit arrangements.

A pharmacy benefit manager is a company that administers prescription drug benefits. In the U.S., PBMs commonly negotiate with drugmakers, arrange pharmacy networks, process prescription claims, and help determine which medicines a plan covers. They can work for employers, insurers, or health plans.

The mechanism is coordination. Drugmakers set prices and offer rebates, pharmacies dispense medicines, insurers or employers fund coverage, and patients obtain prescriptions. A PBM sits between these groups, using contracts and benefit rules to manage payments, coverage, and access. The source identifies PBMs as middlemen overseeing prescription drug spending for employers and workers.

The source does not provide a formal definition or describe every PBM function. Based on established U.S. health-care practice, their central role is to administer and negotiate prescription benefits. The new rule focuses on making their compensation and financial relationships visible to employer clients.

Federal officials estimate that the regulation will apply to more than 70 pharmacy benefit managers and 130,000 employers. Those employers are the PBMs’ clients for prescription drug spending arrangements. The scale makes the rule significant across employer-sponsored drug benefits.

The disclosure requirement starts July 1, 2027. From that date, covered PBMs must report the different fees and compensation they receive from drugmakers, consulting firms, and other entities. The reporting also includes rebates, spread pricing, and certain financial relationships.

This timing gives employers a future point at which they can expect broader payment information from their PBMs. The article does not identify a separate implementation schedule or explain whether every employer arrangement will change immediately. It does state that federal officials expect the disclosures to help produce lower drug costs and more than $800 million in annual savings.

The regulation requires PBMs to disclose all the different fees and compensation they receive. The sources named include drugmakers, consulting firms, and other entities. The rule is designed to show employers how money moves through the prescription-benefit arrangement.

Specific disclosures include drug rebates and spread pricing. Rebates are payments connected to drug purchases or contracts, while spread pricing generally refers to a PBM charging one party more than it pays another. The rule also covers financial relationships with brokers and consultants, such as payments that might affect recommendations or contract choices.

The article does not list every payment category or prescribe how employers must use the information. It does say the relationships could create conflicts of interest. Starting July 1, 2027, employers will receive information intended to make these compensation arrangements more transparent and easier to evaluate.

Rebates and spread pricing can complicate how employers judge the real cost of prescription benefits. A rebate may lower a plan’s net cost, but it can also create a payment tied to a particular drug. Spread pricing can obscure the difference between what a plan pays and what a pharmacy receives.

For example, a PBM might receive a drugmaker rebate while helping determine coverage or preferred placement for that drug. It might also charge an employer more for a prescription than it pays a pharmacy. If the employer cannot see those flows, it may struggle to know whether a recommendation reflects the lowest overall cost.

The article specifically says financial relationships with brokers and consultants could create conflicts of interest. It does not claim that every rebate or spread arrangement is improper. Instead, the rule requires disclosure so employers can identify possible incentives and assess their benefit-management contracts more carefully.

Revealing payments could help employers compare what they pay with the compensation their PBMs receive. With more information, employers may be better positioned to question fees, review contract terms, or seek arrangements that reduce total prescription drug spending. Transparency can also expose relationships that deserve closer scrutiny.

For example, an employer could see a rebate connected to a drug, the spread between a plan payment and a pharmacy payment, or a consultant relationship. It could then ask whether the arrangement lowers the employer’s costs or mainly rewards an intermediary. That information could strengthen negotiations when the employer renews or changes a PBM contract.

The regulation does not guarantee that every employer will obtain the same savings. However, federal officials estimate it will save more than $800 million annually through lower drug costs. The article presents that estimate as a result of the new disclosures and improved employer oversight.

Prescription drug prices and coverage are shaped by several parties. Drugmakers set prices and offer commercial terms. Insurers and employers choose or fund coverage, while PBMs negotiate arrangements, manage formularies and pharmacy networks, and process claims. Pharmacies dispense the medicines, and patients generally pay the required cost share.

The key mechanism is contracting. Employers or insurers hire a PBM to combine purchasing power, negotiate with drugmakers, arrange pharmacy access, and administer benefits. Coverage rules then influence which medicines are preferred and what patients pay at the pharmacy. The source specifically describes PBMs as middlemen overseeing prescription drug spending for employers and workers.

Employers rely on intermediaries because prescription benefits involve many contracts, payments, and operational tasks. The source does not explain that reliance in detail, so this broader description uses established U.S. health-care knowledge. The new rule addresses one concern by requiring greater visibility into PBM compensation and financial relationships.